H. Lundbeck A/S has signalled its confidence in the experimental stroke treatment, desmoteplase, by increasing the size of two ongoing Phase 3 trials of the drug and committing money to the development of possible second-generation compounds. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
